Nisoxetine
| Nisoxetine | |
|---|---|
| Nisoxetine.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 62391-90-8 |
| PubChem | 4495 |
| DrugBank | |
| ChemSpider | 4338 |
| KEGG | D05100 |
Nisoxetine is a selective norepinephrine reuptake inhibitor (NRI) that was initially developed as an antidepressant but was never marketed. It is primarily used in scientific research to study the role of norepinephrine in the central nervous system.
Pharmacology[edit]
Nisoxetine functions by inhibiting the reuptake of norepinephrine (NE) into presynaptic neurons, thereby increasing the concentration of NE in the synaptic cleft and enhancing its activity at postsynaptic receptors. This mechanism is similar to that of other NRIs such as atomoxetine and reboxetine.
Chemical Structure[edit]
The chemical structure of nisoxetine is characterized by a phenoxy group attached to a propanamine chain, with a methoxy group at the ortho position of the phenoxy ring. Its IUPAC name is (RS)-3-(2-Methoxyphenoxy)-3-phenylpropan-1-amine.
Research Applications[edit]
Nisoxetine is widely used in neuroscience research to investigate the effects of increased norepinephrine levels on various physiological and behavioral processes. Studies have utilized nisoxetine to explore its impact on mood disorders, attention-deficit hyperactivity disorder (ADHD), and pain management.
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
